Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 5/20 | 0.40 |
| ▸ | LPL | P06858 | 9/20 | 0.37 |
| ▸ | LIPG | Q9Y5X9 | 9/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA3 | P07451 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | CA6 | P23280 | 1/20 | 0.35 |
| ▸ | CA5A | P35218 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.35 |
| ▸ | CSF1R | P07333 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | TDO2 | P48775 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30416516 | 1.00 | BACE1 (0.40) | BACE1LPLLIPGPRMT5WDR77 | |
| SCHEMBL12077723 | 0.89 | BACE1 (0.42) | BACE1LPLLIPGPRMT5WDR77 | |
| SCHEMBL19049762 | 0.85 | LPL (0.39) | BACE1LPLLIPGPRMT5WDR77 | |
| SCHEMBL30926403 | 0.83 | BACE1 (0.41) | BACE1LPLLIPGPRMT5WDR77 | |
| SCHEMBL24681504 | 0.77 | MKNK1 (0.40) | BACE1LPLLIPGPRMT5WDR77 | |
| SCHEMBL29964196 | 0.77 | MKNK1 (0.40) | BACE1LPLLIPGPRMT5WDR77 | |
| SCHEMBL392410 | 0.75 | CLK4 (0.44) | BACE1LPLLIPGPRMT5WDR77 | |
| SCHEMBL29609304 | 0.75 | CLK4 (0.44) | BACE1LPLLIPGPRMT5WDR77 | |
| SCHEMBL3450261 | 0.75 | LPL (0.43) | LPLLIPGPRMT5WDR77CA1 | |
| SCHEMBL29909145 | 0.75 | LPL (0.43) | LPLLIPGPRMT5WDR77CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3954679-A2 | AMIDE COMPOUNDS FOR THE TREATMENT OF HIV INFECTIONS | Gilead Sciences, Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
| EP-3954679-A2 | AMIDE COMPOUNDS FOR THE TREATMENT OF HIV INFECTIONS | Gilead Sciences, Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
| EP-3409667-B1 | AMIDE COMPOUNDS FOR THE TREATMENT OF HIV INFECTIONS | GILEAD SCIENCES INC (US) | 2021-07-21 | — | — | EP | disclosed |
| EP-3409667-B1 | AMIDE COMPOUNDS FOR THE TREATMENT OF HIV INFECTIONS | GILEAD SCIENCES INC (US) | 2021-07-21 | — | — | EP | disclosed |
| US-20210009555-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2021-01-14 | — | — | US | disclosed |
| US-20210009555-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2021-01-14 | — | — | US | disclosed |
| EP-3409667-A1 | AMIDE COMPOUNDS FOR THE TREATMENT OF HIV INFECTIONS | Gilead Sciences, Inc. (US) | 2018-12-05 | — | — | EP | disclosed |
| EP-3186239-B1 | ANTIRETROVIRAL AGENTS | GILEAD SCIENCES INC (US) | 2018-10-10 | — | — | EP | disclosed |
| US-20180273508-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2018-09-27 | — | — | US | disclosed |
| EP-2961742-B1 | AMIDE COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES INC (US) | 2018-08-01 | — | — | EP | disclosed |
| US-20160108030-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-04-21 | — | — | US | disclosed |
| US-20160108030-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-04-21 | — | — | US | disclosed |
| US-20160083368-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-03-24 | — | — | US | disclosed |
| US-20140303164-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2014-10-09 | — | — | US | disclosed |
| US-20140303164-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2014-10-09 | — | — | US | disclosed |
| US-20140303164-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2014-10-09 | — | — | US | disclosed |
| US-20140296266-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2014-10-02 | — | — | US | disclosed |
| US-20140296266-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2014-10-02 | — | — | US | disclosed |
| US-20140296266-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2014-10-02 | — | — | US | disclosed |
| WO-2014134566-A2 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296266-A1 | THERAPEUTIC COMPOUNDS | HAVCR2, SARS1, G6PD | BACE1 393/4885LPL 1208/4885LIPG 1111/4885 |
| US-20180273508-A1 | THERAPEUTIC COMPOUNDS | HAVCR2, SARS1, RPL35 | BACE1 462/4885LPL 1195/4885LIPG 1171/4885 |
| US-20210009555-A1 | THERAPEUTIC COMPOUNDS | HAVCR2, SARS1, RPL35 | BACE1 462/4885LPL 1195/4885LIPG 1171/4885 |
| US-20160108030-A1 | THERAPEUTIC COMPOUNDS | HAVCR2, SARS1, RPL35 | BACE1 462/4885LPL 1195/4885LIPG 1171/4885 |
| US-20160083368-A1 | THERAPEUTIC COMPOUNDS | HAVCR2, SARS1, G6PD | BACE1 393/4885LPL 1208/4885LIPG 1111/4885 |
| US-20140303164-A1 | THERAPEUTIC COMPOUNDS | HAVCR2, SARS1, G6PD | BACE1 393/4885LPL 1208/4885LIPG 1111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.